U.S. Markets open in 1 hr 40 mins
  • S&P Futures

    4,145.75
    -37.75 (-0.90%)
     
  • Dow Futures

    34,485.00
    -183.00 (-0.53%)
     
  • Nasdaq Futures

    13,146.25
    -210.50 (-1.58%)
     
  • Russell 2000 Futures

    2,172.60
    -37.00 (-1.67%)
     
  • Crude Oil

    64.24
    -0.68 (-1.05%)
     
  • Gold

    1,841.00
    +3.40 (+0.19%)
     
  • Silver

    27.58
    +0.08 (+0.30%)
     
  • EUR/USD

    1.2167
    +0.0032 (+0.2677%)
     
  • 10-Yr Bond

    1.6020
    0.0000 (0.00%)
     
  • Vix

    21.68
    +4.99 (+29.90%)
     
  • GBP/USD

    1.4141
    +0.0020 (+0.1400%)
     
  • USD/JPY

    108.6400
    -0.2010 (-0.1847%)
     
  • BTC-USD

    55,443.86
    -2,802.78 (-4.81%)
     
  • CMC Crypto 200

    1,592.96
    +31.66 (+2.03%)
     
  • FTSE 100

    6,962.09
    -161.59 (-2.27%)
     
  • Nikkei 225

    28,608.59
    -909.71 (-3.08%)
     

UroGen Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 18, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Conference Call and Webcast Scheduled for Thursday, March 18, 2021 at 8:30 AM ET

UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, March 18, 2021, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30 AM Eastern Time.

Audio Webcast
The webcast will be made available on the Investors section of the Company’s website at http://investors.urogen.com. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.

Dial-In Information
Live (U.S. / Canada): (855) 765-5685
Live (International): (615) 247-5916
Confirmation number: 9043018

About UroGen Pharma Ltd.
UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005260/en/

Contacts

INVESTOR CONTACT:
Sara Blum Sherman
Head of Investor Relations
investors@urogen.com
609-467-4975

MEDIA CONTACT:
Eric Van Zanten
Senior Director, Communications
Eric.VanZanten@urogen.com
610-529-6219